KLRS Kalaris Therapeutics Inc.

  1. Stocks
  2. Healthcare
  3. NASDAQ: KLRS

Price (delayed)

$3.12

Market cap

$74.27M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.02

Enterprise value

$32M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 12
Highlights
KLRS's EPS has soared by 96% YoY and by 6% QoQ
The net income is up by 46% year-on-year
The equity has declined by 16% since the previous quarter but it rose by 9% year-on-year
The quick ratio has declined by 11% since the previous quarter and by 7% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.allovir.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of KLRS

KLRS stock price

How has the Kalaris Therapeutics stock price performed over time
Intraday
-3.7%
1 week
-1.89%
1 month
-24.82%
1 year
-34.59%
YTD
-63.03%
QTD
-23.34%

Financial performance

How have Kalaris Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$47.76M
Net income
-$44.26M
Gross margin
N/A
Net margin
N/A
The net income is up by 46% year-on-year
The operating income has grown by 29% YoY

Price vs fundamentals

How does KLRS's price correlate with its fundamentals

Growth

What is Kalaris Therapeutics's growth rate over time

Valuation

What is Kalaris Therapeutics stock price valuation
P/E
N/A
P/B
1.29
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
KLRS's EPS has soared by 96% YoY and by 6% QoQ
The price to book (P/B) is 33% less than the last 4 quarters average of 2.0 and 29% less than the 5-year quarterly average of 1.9
The equity has declined by 16% since the previous quarter but it rose by 9% year-on-year

Efficiency

How efficient is Kalaris Therapeutics business performance
KLRS's return on equity has surged by 69% year-on-year
The return on assets has surged by 57% year-on-year
Kalaris Therapeutics's return on invested capital has increased by 31% QoQ

Dividends

What is KLRS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KLRS.

Financial health

How did Kalaris Therapeutics financials performed over time
The total assets is 138% greater than the total liabilities
The quick ratio has declined by 11% since the previous quarter and by 7% year-on-year
The current ratio has contracted by 10% from the previous quarter and by 8% YoY
Kalaris Therapeutics's debt is 98% less than its equity
The equity has declined by 16% since the previous quarter but it rose by 9% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.